Cargando…
Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation
With the rapid growth of advanced nanoengineering strategies, there are great implications for therapeutic immunostimulators formulated in nanomaterials to combat cancer. It is crucial to direct immunostimulators to the right tissue and specific immune cells at the right time, thereby orchestrating...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762307/ https://www.ncbi.nlm.nih.gov/pubmed/36257824 http://dx.doi.org/10.1002/advs.202204335 |
_version_ | 1784852837496258560 |
---|---|
author | Yu, Meihua Yang, Wei Yue, Wenwen Chen, Yu |
author_facet | Yu, Meihua Yang, Wei Yue, Wenwen Chen, Yu |
author_sort | Yu, Meihua |
collection | PubMed |
description | With the rapid growth of advanced nanoengineering strategies, there are great implications for therapeutic immunostimulators formulated in nanomaterials to combat cancer. It is crucial to direct immunostimulators to the right tissue and specific immune cells at the right time, thereby orchestrating the desired, potent, and durable immune response against cancer. The flexibility of nanoformulations in size, topology, softness, and multifunctionality allows precise regulation of nano‐immunological activities for enhanced therapeutic effect. To grasp the modulation of immune response, research efforts are needed to understand the interactions of immune cells at lymph organs and tumor tissues, where the nanoformulations guide the immunostimulators to function on tissue specific subsets of immune cells. In this review, recent advanced nanoformulations targeting specific subset of immune cells, such as dendritic cells (DCs), T cells, monocytes, macrophages, and natural killer (NK) cells are summarized and discussed, and clinical development of nano‐paradigms for targeted cancer immunotherapy is highlighted. Here the focus is on the targeting nanoformulations that can passively or actively target certain immune cells by overcoming the physiobiological barriers, instead of directly injecting into tissues. The opportunities and remaining obstacles for the clinical translation of immune cell targeting nanoformulations in cancer therapy are also discussed. |
format | Online Article Text |
id | pubmed-9762307 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97623072022-12-20 Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation Yu, Meihua Yang, Wei Yue, Wenwen Chen, Yu Adv Sci (Weinh) Reviews With the rapid growth of advanced nanoengineering strategies, there are great implications for therapeutic immunostimulators formulated in nanomaterials to combat cancer. It is crucial to direct immunostimulators to the right tissue and specific immune cells at the right time, thereby orchestrating the desired, potent, and durable immune response against cancer. The flexibility of nanoformulations in size, topology, softness, and multifunctionality allows precise regulation of nano‐immunological activities for enhanced therapeutic effect. To grasp the modulation of immune response, research efforts are needed to understand the interactions of immune cells at lymph organs and tumor tissues, where the nanoformulations guide the immunostimulators to function on tissue specific subsets of immune cells. In this review, recent advanced nanoformulations targeting specific subset of immune cells, such as dendritic cells (DCs), T cells, monocytes, macrophages, and natural killer (NK) cells are summarized and discussed, and clinical development of nano‐paradigms for targeted cancer immunotherapy is highlighted. Here the focus is on the targeting nanoformulations that can passively or actively target certain immune cells by overcoming the physiobiological barriers, instead of directly injecting into tissues. The opportunities and remaining obstacles for the clinical translation of immune cell targeting nanoformulations in cancer therapy are also discussed. John Wiley and Sons Inc. 2022-10-18 /pmc/articles/PMC9762307/ /pubmed/36257824 http://dx.doi.org/10.1002/advs.202204335 Text en © 2022 The Authors. Advanced Science published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Yu, Meihua Yang, Wei Yue, Wenwen Chen, Yu Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation |
title | Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation |
title_full | Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation |
title_fullStr | Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation |
title_full_unstemmed | Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation |
title_short | Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation |
title_sort | targeted cancer immunotherapy: nanoformulation engineering and clinical translation |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762307/ https://www.ncbi.nlm.nih.gov/pubmed/36257824 http://dx.doi.org/10.1002/advs.202204335 |
work_keys_str_mv | AT yumeihua targetedcancerimmunotherapynanoformulationengineeringandclinicaltranslation AT yangwei targetedcancerimmunotherapynanoformulationengineeringandclinicaltranslation AT yuewenwen targetedcancerimmunotherapynanoformulationengineeringandclinicaltranslation AT chenyu targetedcancerimmunotherapynanoformulationengineeringandclinicaltranslation |